Microbial Metabolism and Disease
- 1st Edition - March 18, 2021
- Latest edition
- Author: Elena L. Paley
- Language: English
- Paperback ISBN:9 7 8 - 0 - 3 2 3 - 8 8 4 4 5 - 7
- eBook ISBN:9 7 8 - 0 - 3 2 3 - 8 8 4 4 6 - 4
Microbiome Metabolic Pathways and Disease provides insight into the interaction of microbial metabolic pathways in the human body and the impact these can have on a variety o… Read more
Microbiome Metabolic Pathways and Disease provides insight into the interaction of microbial metabolic pathways in the human body and the impact these can have on a variety of diseases. By analyzing these pathways the book seeks to investigate how these metabolic processes can be targeted and manipulated in order to treat various disorders and diseases. Topics covered in the book include microbial shikimate pathways, protein biosynthesis, tryptophan metabolites, microbiome metabolic engineering, fecal microbiota transplantation, and virulence factors. Additionally, a variety of conditions are covered, such as disorders associated with metabolic syndromes, serotonin syndromes, Alzheimer’s disease, and Covid-19, providing a detailed overview of how metabolic pathways of microbiome can impact health and disease in the human body.
- Explores microbial metabolic pathways in the human body and implications for disease
- Investigates specific steps involved in metabolic reactions in the human microbiome, including shikimate pathways and tryptophan pathways
- Considers a variety of diseases and disorders, such as Alzheimer’s disease, metabolic syndromes, Crohn’s disease and Covid-19
- Includes analysis of various amino acids and enzymes in microbial and human cells and how these can impact health
Molecular biologists, biochemists, microbiologists, pharmacologists. Graduate, PhD and postdoctoral researchers working in the areas of molecular biology, biochemistry, microbiology, biomedicine and related fields
1. Naturally occurring affectors of initial step of protein biosynthesis1.1 Abstract1.2 Introduction1.3 Experimental evidences supporting the concept1.3.1 Tryptamine-induced neurodegeneration in cell and animal models1.3.2 Alzheimer’s disease (AD) is a systemic widespread disease1.3.3 Seizures and myoclonus in Alzheimer's disease and in tryptamine-treated animals1.3.4 Serotonin (5-HT) or tryptamine syndrome1.3.5 Metabolic syndrome1.3.6 Tryptamine, biogenic amines (BA) and polyamines affect tRNA aminoacylation and protein biosynthesis1.3.7 Protein biosynthesis in Alzheimer’s disease and in cancer1.3.8 Mutations of genes encoding cytoplasmic (WARS) and mitochondrial (WARS2) TrpRS leading to TrpRS deficiency, Parkinsonism and cognitive impairment1.3.9 The accumulation of defective proteins induces antigenicity1.3.10 Conclusion
2. Physicochemical, biochemical and cell biology properties and byproducts of tryptamine and other “trace” amines
3. Tryptophan metabolites and biogenic amines in physical exercises
4. Tryptamine in inflammation and regulation of gene transcription
5. Genes encoding mammalian, plant and microbial aromatic amino acid decarboxylase5.1 Mammalian aromatic acid decarboxylase5.2 Bacterial aromatic L-amino acid decarboxylases5.3 Fungal pyridoxal-dependent aromatic-L-amino-acid decarboxylase5.4 Plant tryptophanyl-tRNA synthetase5.5 Conclusion
6. Decarboxylases producing tryptamine and other biogenic amines in human microbiome
7. Microbial shikimate pathway in diseases7.1 Apicomplexan parasites7.2 Effect of tryptamine and other tryptophan related compounds on shikimate pathway enzymes7.3 Pyridoxal phosphate (PLP)-dependent enzymes7.4 Metabolic engineering7.5 Inhibitors of shikimate pathway enzymes7.6 Conclusion
8. Biogenic amines in fasting, feeding and stress conditions8.1 Fasting and feeding8.2 Anorectic effect8.3 Stress factors8.4 Stress and mucus8.5 Irritable bowel syndrome: poor sleep8.6 Conclusions
9. Metabolites of shikimate and tryptophan pathways in Corona virus disease (COVID-19)9.1 Comparison of statistics for age-related diseases COVID-19 and Alzheimer’s disease9.2 Proteomic and metabolomic profiling of sera from COVID-19 patients and further discussion9.3 Postmortem studies of COVID-19 patients in different countries9.4 Conclusions
10. Virulence factors10.1 Bacteria and virus interactions in influenza10.2 Decarboxylase and viral infection10.3 Emerging data suggest that microbial tryptophan catabolites resulting from shikimate pathway, diet and human proteolysis are influencing host health10.4 Toxicological effects of biogenic amines and postmortem examinations of Serotonin Syndrome cases10.4.1 Toxicological effects of biogenic amines10.4.2 Postmortem study of Serotonin Syndrome cases10.5 Biogenic amines and amino acid decarboxylases as virulence factors10.5.1 Tyramine, histamine, putrescine as virulence factors10.5.2 Tryptamine as virulence and anaphylaxis factor10.5.3 Spermine, spermidine, tyramine and tryptamine in viral infection11. Relation of human gut Alzheimer’s disease associated sequence (ADAS) with shikimate pathway metabolites11.1 Alterations in human gut microbiome shikimate pathway and metabolites of aromatic amino acids linked to Alzheimer’s disease and associated metabolic disorders11.2 Ubiquinone, a substrate of Na(+)-transporting NADH: Ubiquinone reductase related to ADAS11.3 Shikimate pathway metabolites 4-hydroxybenzoate, 3–hydroxybenzoate, benzoate and quinate in human fecal samples11.4 Aromatic amino acids (AAA) and biogenic amines in human gut
12. Benefits of using fecal microbiota transplantation as treatment have been controversial
13. Shikimate pathway enzymes in human microbiome13.1 Shikimate pathway and its inhibitor pesticide glyphosate in general human population and in diseases13.2 Human microbial metabolic capacity for production of shikimate pathway metabolites13.3 Conclusions
14. Tryptophan operon in human microbiome and inhibitors of tryptophan operon enzymes
15. Antibodies to tryptamines
16. Cell death in Alzheimer's disease brain and tryptamine-treated cells
- Edition: 1
- Latest edition
- Published: March 18, 2021
- Language: English
EP
Elena L. Paley
Dr. Paley is Cofounder of the nonprofit Stop Alzheimers Corp and Founder of Expert Biomed, Inc. She holds a PhD degree in biology with specialization in molecular biology from the Engelhardt Institute of Molecular Biology of the Russian Academy of Sciences in the Laboratory of Lev L. Kisselev. Dr. Paley’s research focuses mainly on protein biosynthesis in biology and diseases and is conducted in collaboration with Harvard University, Brandeis University, the University of Miami, Tel Aviv University, the Institut des Vaisseaux et du Sang (Paris, France), and the University of Texas at San Antonio. She is Adjunct Professor at Nova Southeastern University, FL, United States, and is inventor in patents issued and pending. Dr. Paley has previously published 4 books with Elsevier.
Affiliations and expertise
Adjunct Professor at Nova Southeastern University, FL,, USARead Microbial Metabolism and Disease on ScienceDirect